Eine Kamera ist auf eine reflektierende Glasscheibe gerichtet.
© DZIF

News

All current DZIF news can be found here.

Produced by the National Institute of Allergy and Infectious Diseases (NIAID), this digitally colorized scanning electron microscopic (SEM) image, depicts a large group of orange-colored, rod shaped, Mycobacterium tuberculosis bacteria, which cause tuberculosis (TB) in human beings.
© National Institute of Allergy and Infectious Diseases (NIAID)

New S3 Guideline on Tuberculosis Prevention Among New Migrants Published

Just in time for today’s World Tuberculosis Day, the new S3 guideline on tuberculosis prevention among newly arrived migrants has gone online at the Association of Scientific Medical Societies (AWMF)

Prof. Lange (center) receives the Oskar-Medical-Prize
© Mike Auerbach

Prof. Christoph Lange awarded the 2025 Oskar Medical Prize

Prof. Christoph Lange, Head of the Clinical Tuberculosis Infrastructure at the German Center for Infection Research (DZIF) and Medical Director of the Borstel Research Center, Leibniz Lung Center, has

The GUARDIAN project uses AI to combat antibiotic-resistant bacteria.
© JLU (Generated by AI using ChatGPT)

Kickoff meeting for the GUARDIAN research project in Giessen marks the launch of interdisciplinary collaboration against antibiotic resistance

At the DZIF partner site in Giessen, a ceremonial kickoff meeting marked the launch of the GUARDIAN research project, which is funded with 3.5 million euros by the Federal Ministry of Research

Model of a hepatitis E virus particle
© RUB, Marquard

Promising active substance against hepatitis E identified

Around 70,000 people die each year from infections with the hepatitis E virus. There is currently neither a vaccine nor a specific drug against this virus. This could change with the identification of

Symbolic photo, lab work
© Vic Josh/adobe.stock.com

Innovation in Tuberculosis Treatment: New International Study Launched

The Institute of Infectious Diseases and Tropical Medicine has announced the inclusion of the first study participant in the STEP2C Stage 3 trial. The study is part of the international UNITE4TB

Seven people standing in a laboratory room next to a large metal device, with pipes, ducts, and technical equipment visible in the background.
© DZIF

Close collaboration between the Helmholtz Munich Biobank and the DZIF Transplant Cohort

The DZIF Transplant Cohort (Tx Cohort) provides interested researchers and study groups with extensive medical data on over 3,000 transplant recipients, focusing on infections. The cohort data is

A man and a woman in blue surgical gowns and blue gloves are looking at a monitor. The woman is holding medical equipment in her hands. They are surrounded by other medical equipment.
© MHH/Karin Kaiser

Precision medicine for the liver

Approximately one in 10,000 people in Germany is affected by primary sclerosing cholangitis (PSC). In order to digest fats from food, the intestine needs bile. This is produced in the liver and from

Christoph Lange accepts the DZIF Prize for Translational Infection Research
© DZIF/Dirk Baumbach

Christoph Lange receives the DZIF Prize for Translational Infection Research 2025

He is one of the world's leading clinical researchers in the field of tuberculosis (TB): Prof. Dr. Dr. h. c. Christoph Lange has been awarded the DZIF Prize for Translational Infection Research 2025

Prof. Achim Hörauf in Expertenkomitee des Mectizan Donation Program berufen
© Universitätsklinikum Bonn/R. Müller

Achim Hörauf elected as a member of the Mectizan Expert Committee

Prof. Achim Hörauf, Director of the Institute of Medical Microbiology, Immunology and Parasitology at the University Hospital Bonn and scientist at the German Center for Infection Research (DZIF), has

The scientists involved in the study: Prof. Florian Klein, Dr. Lutz Gieselmann, and Dr. Malena Rohde (from left to right).
© Klaus Schmidt

HIV antibody opens new approaches for vaccine development and combination therapies

An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site and overcomes previous limitations of known antibodies. The study, led by